Schrödinger Consensus Price Target Increased by 16.67% to $25.50
The average one-year price target for Schrödinger (NASDAQGS:SDGR) (DB:43Z) has been revised to $25.50 / share. This is an increase of 16.67% from the prior estimate of $21.86 dated September 29, 2026. These figures represent aggregate analyst targets and do not constitute a recommendation by Fintel.
The latest analyst targets range from a low of $17.17 to a high of $33.60 / share. The average price target represents an increase of 12.83% from the latest reported closing price of $22.60 / share on October 22, 2026. The target range has widened by +14.65%, with a current width of $16.43 compared to the prior width of $14.33.
Historical target data shows the mean target was $21.86 on August 28, 2026, September 15, 2026, and October 2, 2026, before adjusting to $25.50 on October 23, 2026. This current target represents a +27.74% change from the 90-day baseline target of June 30, 2026. Over a twelve-month period, the observed high mean target was $27.77 on December 21, 2025, and the observed low mean target was $19.38 on August 4, 2026.
Schrödinger's latest reported closing price was $22.60 on October 22, 2026. In its latest quarterly report on August 5, 2026, the company recorded actual EPS of 0.08 (estimated EPS -0.4916) and actual revenue of $58,889,000.00 versus estimated revenue of $48,173,070.00. The company's upcoming third-quarter earnings for 2026 are scheduled for November 11, 2026.
Analyst sentiment as of October 1, 2026 was 76.9% positive and 23.1% hold (unchanged from September 1, 2026). Recent analyst actions include UBS maintaining a Neutral grade on October 20, 2026; Keybanc maintaining an Overweight grade on October 16, 2026; TD Cowen maintaining a Buy grade on October 13, 2026; and BMO Capital maintaining an Outperform grade on October 12, 2026.
In the broader Biotechnology sub-industry (24 companies), 8 companies had their targets raised, 2 were lowered, and 14 remained unchanged. The sub-industry median revision percent is 0.00%, with a median implied change of +103.96%.
| Company | Target revision | Implied change |
|---|---|---|
| Recursion Pharmaceuticals | +1.80% | +93.17% |
| Certara | +6.96% | -8.24% |
| Relay Therapeutics | 0.00% | +51.68% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.